(S)-ethyl 1-((S)-2-hydroxypropanoyl)piperidine-3-carboxylate

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: (S)-ethyl 1-((S)-2-hydroxypropanoyl)piperidine-3-carboxylate
• 英文别名: ethyl (3S)-1-[(2S)-2-hydroxypropanoyl]piperidine-3-carboxylate
• 化学式: C₁₁H₁₉NO₄
• 分子量: 229.276
• InChiKey: DVYXSUKNFUZDOJ-IUCAKERBSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  16
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.82
• 拓扑面积：
  66.8
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  L-乳酸 、 (S)-3-哌啶甲酸乙酯 在 N,N-二异丙基乙胺 、 N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 以50%的产率得到(S)-ethyl 1-((S)-2-hydroxypropanoyl)piperidine-3-carboxylate
  参考文献：
  名称：

  [EN] COUMARIN DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND USES THEREOF FOR THE TREATMENT OF CANCER
  [FR] DÉRIVÉS DE COUMARINE, LEURS PROCÉDÉS DE PRÉPARATION ET LEURS UTILISATIONS DANS LE TRAITEMENT DU CANCER

  摘要：

  该发明提供了新型香豆素衍生物作为特异性线粒体RNA聚合酶抑制剂，用于治疗癌症。

  公开号：

  WO2019057821A1

文献信息

• Coumarin derivatives, processes for their preparation and uses thereof for the treatment of cancer
  申请人：Lead Discovery Center GmbH

  公开号：US11111238B2

  公开（公告）日：2021-09-07

  The invention provides novel coumarin derivatives as specific mitochondrial RNA polymerase inhibitors for the treatment of cancer.

  本发明提供了新型香豆素衍生物，作为治疗癌症的特异性线粒体 RNA 聚合酶抑制剂。
• COUMARIN DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND USES THEREOF FOR THE TREATMENT OF CANCER
  申请人：Lead Discovery Center GmbH

  公开号：US20200291011A1

  公开（公告）日：2020-09-17

  The invention provides novel coumarin derivatives as specific mitochondrial RNA polymerase inhibitors for the treatment of cancer.
• QUINOLINE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND USES THEREOF FOR THE TREATMENT OF CANCER
  申请人：Lead Discovery Center GmbH

  公开号：US20220169616A1

  公开（公告）日：2022-06-02

  The present invention relates to compounds of the general formula (I): (I), wherein V, W, M, R, R and Y have the designations cited below, or a pharmaceutically or veterinary acceptable salt, hydrate or solvate thereof, and to processes for the preparation of compounds of the general formula (I) or a pharmaceutically or veterinary acceptable salt, hydrate or solvate thereof. The invention also relates to compounds of the general formula (I) or a pharmaceutically or veterinary acceptable salt, hydrate or solvate thereof for use as a medicament. Further, the invention relates to compounds of the general formula (I) or a pharmaceutically or veterinary acceptable salt, hydrate or solvate thereof for use in the treatment of cancer. Moreover, the invention relates to compounds of the general formula (I) or a pharmaceutically or veterinary acceptable salt, hydrate or solvate thereof for treating cancer in simultaneous, alternating or subsequent combination with another cancer therapy.